Effectiveness of the Chinese Herbal Formula TongXieYaoFang for Irritable Bowel Syndrome: A Systematic Review

2006 ◽  
Vol 12 (4) ◽  
pp. 401-407 ◽  
Author(s):  
Zhaoxiang Bian ◽  
Taixiang Wu ◽  
Liang Liu ◽  
Jiangxia Miao ◽  
Honfat Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Irritable Bowel Syndrome ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

scholarly journals JCM-16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS-Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Hong-Yan Qin ◽  
Hai-Tao Xiao ◽  
Fung-Ping Leung ◽  
Zhi-Jun Yang ◽  
Justin C. Y. Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Analgesic Effect ◽  
Tryptophan Hydroxylase ◽  
Herbal Formula ◽  
Mechanical Stimuli ◽  
Visceral Hyperalgesia ◽  
Cell Hyperplasia ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

The present study aimed to investigate the analgesic effect of JCM-16021, a revised traditional Chinese herbal formula, on postinflammatory irritable bowel syndrome (PI-IBS) in rats. The trinitrobenzene sulfonic (TNBS) acid-induced PI-IBS model rats were orally administrated with different doses of JCM-16021 (1.2, 2.4, and 4.8 g/kg/d) for 14 consecutive days. The results showed that JCM-16021 treatment dose-dependently attenuated visceral hyperalgesia in PI-IBS rats. Further, the colonic enterochromaffin (EC) cell number, serotonin (5-HT) content, tryptophan hydroxylase expression, and mechanical-stimuli-induced 5-HT release were significantly ameliorated. Moreover, the decreased levels of mucosal cytokines in PI-IBS, especially the helper T-cell type 1- (Th1-) related cytokine TNF-α, were also elevated after JCM-16021 treatment. These data demonstrate that the analgesic effect of JCM-16021 on TNBS-induced PI-IBS rats may be medicated via reducing colonic EC cell hyperplasia and 5-HT availability.

scholarly journals Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Qian Huang ◽  
Xiaohui Guo ◽  
Meiling Xuan ◽  
Wenwei Ouyang ◽  
Zehuai Wen
Keyword(s):  
Atopic Dermatitis ◽  
Irritable Bowel Syndrome ◽  
Observational Study ◽  
Severity Index ◽  
Protocol Design ◽  
Herbal Formula ◽  
High Quality ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

Introduction. Atopic dermatitis (AD) and diarrhea-predominant irritable bowel syndrome (IBS-D) are two recurrent diseases with limited effective treatments. In Chinese Medicine (CM) theory, they may share dampness pattern as the same dominant pathogenesis at a certain stage and, thus, can be treated with the same method. While Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been reported as an effective dampness-resolving therapy for both AD and IBS-D, further high-quality clinical studies are still needed. In addition, HXZQ lacks accurate clinical positioning based on CM patterns. Therefore, we utilize a master protocol design to evaluate HXZQ for dampness pattern simultaneously in AD and IBS-D, with the aim of identifying the pattern-defined population of HXZQ. Methods and Analysis. This master protocol design includes two randomized controlled trials (RCTs) and a real-world observational study. Based on two registry cohorts of AD and IBS-D, patients with dampness pattern will be enrolled in the RCTs to receive either HXZQ oral liquid or a placebo for 4 weeks and then will be followed up for another 4 weeks, while patients with nondampness pattern will constitute the observational study and experience a 12-week follow-up. A total of 678 AD patients and 322 IBS-D patients will be recruited from 14 hospitals in China over a 3-year period. The eczema area and severity index (EASI) and the proportion of responders for adequate relief (AR) are the primary outcomes in AD and IBS-D, respectively. Analysis will be undertaken separately in each substudy, and then an overall analysis combining multiple subgroups will be performed to comprehensively investigate the effect of HXZQ. Discussion. This study will provide high-quality efficacy evidence of HXZQ for AD and IBS-D patients and give an example of postmarketing evaluation for CM products under the pattern dominating different disease research model. The study is registered with ChiCTR1900026700 and ChiCTR1900026837.

scholarly journals The Chinese herbal formula Huoxiang Zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiaohui Guo ◽  
Meiling Xuan ◽  
Huan Zheng ◽  
Shumin Qin ◽  
Haomeng Wu ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Outcome Measures ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Life Questionnaire ◽  
Herbal Formula ◽  
Efficacy And Safety ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel

Abstract Background Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common chronic digestive disease. Recent observational studies have reported that the Chinese herbal formula Huoxiang Zhengqi (HXZQ) can relieve IBS-D symptoms, but no high-level evidence is presented. Therefore, we want to evaluate the efficacy and safety of HXZQ for IBS-D patients. Methods This is a double-blind, randomized, placebo-controlled trial. The 212 eligible patients with IBS-D will be randomly assigned to receive either HXZQ oral liquid or a placebo, at a 1:1 ratio, for 4 weeks with a 4-week follow-up period. Adequate relief will be the primary outcome measures. IBS symptom severity score, IBS quality-of-life questionnaire, EQ-5D-5L, and Chinese medicine symptom questionnaire will be the secondary outcome measures. Discussion This trial aims to demonstrate the efficacy and safety of HXZQ for IBS-D, which is expected to be an effective IBS-D treatment. Trial registration The trial was registered with the Chinese Clinical Trial Registry, ChiCTR1900026837. Registered on 24 October 2019.

scholarly journals Xiaoyao-san, a traditional Chinese herbal formula, for the treatment of irritable bowel syndrome

Medicine ◽  
2021 ◽  
Vol 100 (10) ◽  
pp. e24019
Author(s):  
JiHo Lee ◽  
Won-Suk Sung ◽  
Eun-Jung Kim ◽  
Young Woo Kim
Keyword(s):  
Irritable Bowel Syndrome ◽  
Herbal Formula ◽  
Chinese Herbal Formula ◽  
Chinese Herbal ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document